Rein Therapeutics closes $50 million stock offering at $1.00 per share
Rein Therapeutics closed on May 4, 2026 the sale of 50,000,000 shares of common stock at $1.00 per share under an April 30 underwriting agreement with Konik Capital Partners, with net proceeds expected to be about $46.1 million. The company said the proceeds, with existing cash, are expected to fund operations into 2028 and its Phase 2 LTI-03 trial through completion. The offering adds shares outstanding and the filing also includes warrants to the underwriter and to Bios entities, which dilute existing shareholders.
Key points
- 50,000,000 shares sold at $1.00 per share before underwriting discounts; closed May 4, 2026
- Expected net proceeds of about $46.1 million; underwriter has a 45-day option for up to 7,500,000 more shares
- Underwriter warrants for up to 3% of shares sold, exercisable at $1.50 per share through April 30, 2031
- Bios entities to receive warrants for 3,000,000 shares at $1.00 per share and defer conversion of 12,232 Series X preferred shares
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.